STOCK TITAN

Stevanato Group to Report Fourth Quarter Financial Results on March 8, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the fourth quarter and full year of fiscal year 2021 on Tuesday, March 8, 2022, at 6:30 a.m. Eastern Time (12:30 Central European Time).

The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14:30 Central European Time) on Tuesday, March 8, 2022. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the slide presentation, please visit the “Financial Results” page, under the Financial Information tab of the Company's Investor Relations section of its website.

To participate on the call please dial:

United States: +1 646 664 1960
United Kingdom: +44 020 3936 2999
Canada: +1 613 699 6539
Italy: +39 06 9450 1060
All other locations: +44 20 3936 2999

Access Code: 156733

Preregistration:
Listeners are encouraged to preregister for the call via the following link:
https://www.incommglobalevents.com/registration/client/10119/stevanato-full-year-results/
whereupon you will be provided with a unique dial-in number and access code.

For Participants that do not preregister:
A live broadcast of the conference call will also be available online at the following link: www.incommuk.com/customers/online (access code 156733).

Replay:
An online archive of the broadcast will be available at the website shortly after the live call and will be available through Tuesday, March 22, 2022. The recording will be accessible via the following link: https://www.incommglobalevents.com/replay/7538/stevanato-full-year-results/ (access code 358435).

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. Stevanato Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.

For more information, please visit www.stevanatogroup.com

Investor Relations

Lisa Miles

lisa.miles@stevanatogroup.com

Media

Stevanato Group

media@stevanatogroup.com

Source: Stevanato Group S.p.A.

Stevanato Group S.p.A.

NYSE:STVN

STVN Rankings

STVN Latest News

STVN Stock Data

5.65B
41.66M
2.13%
77.59%
0.87%
Glass Container Manufacturing
Manufacturing
Link
United States of America
Piombino Dese

About STVN

founded in 1949, stevanato group is committed to create systems, processes and services that guarantee the integrity of parenteral medicines. it is comprised of two operational divisions: - pharmaceutical systems (ompi and balda brands): specialized in ready-to-use glass containers and bulk primary packaging (syringes, cartridges, vials and ampoules); high quality and high precision plastic solutions for diagnostic, pharmaceutical and medical device applications. - engineering systems (spami, optrel, innoscan and svm brands): specialized in glass forming technology, inspection systems, assembly, packaging machines and serialization solutions for the pharmaceutical industry. these two divisions enjoy a close, synchronous relationship, featuring daily exchanges which ensure that stevanato group has complete control over the entire production process, from purchasing the finest raw materials to offering exceptional after-sales customer service. the group also benefits from the sglab activ